June 24, 2022
June 24, 2022 – The U.S. FDA has approved two new indications for Breyanzi® (lisocabtagene maraleucel),
in the treatment of large B-cell lymphoma (LBCL).
- Have any questions?
- +1-888-INTL-SOS
- support@globalreachhealth.com
International Medical Insurance
June 23, 2022
June 23, 2022 – Tafinlar® (dabrafenib) and Mekinist® (trametinib), both made by Novartis, are now approved for combination use to treat unresectable or
June 22, 2022
June 22, 2022 – The U.S. FDA has approved an expanded indication for VaxneuvanceTM (pneumococcal 15-
valent conjugate vaccine) to include pediatric patients
June 22, 2022
June 22, 2022 – Zulresso (brexanolone) has obtained an expanded indication to treat postpartum depression (PPD) in patients who are at least 15 years old
June 20, 2022
June 30, 2022 – Drug manufacturer Alfasigma has withdrawn Zelnorm® (tegaserod) from the U.S. market.
According to the company, the withdrawal is the result of a business
June 17, 2022
June 17, 2022 – Skyrizi® (risankizumab-rzaa – AbbVie) is now the first and only specific interleukin-23 (IL-
23) inhibitor to receive FDA approval for treating moderately to
June 17, 2022
June 17, 2022 – Comirnaty® (COVID-19 vaccine, mRNA) and Spikevax® (COVID-19 vaccine, mRNA) have been granted emergency use authorization
June 16, 2022
June 16, 2022 – The U.S. FDA has approved Imcivree® (setmelanotide – Rhythm Pharmaceuticals) to treat
of obesity and control hunger in patients who are at